According to the latest market report published by Credence Research, Inc. “Asthma and COPD Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025,” the global asthma and COPD market was valued at US$ 39,021.2 Mn in 2016, and is expected to reach US$ 56,507.7 Mn by 2025, expanding at a CAGR of 4.2% from 2017 to 2025.

Browse the full report Asthma and COPD Market - Growth, Future Prospects and Competitive Analysis, and Forecast, 2017 – 2025 at http://www.credenceresearch.com/report/asthma-and-copd-drugs-market

Market Insights

Globally, asthma and COPD is one the leading chronic respiratory diseases, with high prevalence and increasing health care and economic burden. Thus, disease represent a lucrative market for pharmaceutical companies. COPD is rated to be the fourth most common cause of mortality, and expected to reach third position by 2030, in case the risk such as smoking, pollution is not addressed. Gradually over the period of time the treatment of asthma and COPD shows improvement, with novel drugs and treatment strategies, along with usage of non-pharmacologic treatment. It has being observed there is being surge in prevalence of asthma and COPD in developed and developing countries. In developed countries, there is being rise in prevalence of asthma due to lifestyle changes in terms of food habit, low level of exercise, etc., while in developing countries the prevalence is due to pollution and smoking.

The global asthma and COPD market is segmented by drug type into anti-inflammatory drugs, bronchodilator monotherapy and combination drugs. Anti-inflammatory drugs includes corticosteroids, anti-leukotrienes and monoclonal antibodies. Bronchodilator monotherapy includes short-acting beta2-agonist (SABAs) and long-acting beta2-agonist (LABAs) and anticholinergic drugs. Amongst all, combination therapy of long-acting beta2 agonist (LABA)/ inhaled corticosteroid (ICS) dominates the market. The combination therapy that include Symbicort (AstraZeneca), Advair (GlaxoSmithKline) is most preferred treatment against asthma/ COPD, due to better efficacy and less side effects.

As of the current market scenario, North America together dominate the global asthma and COPD market followed by the European market. Rising prevalence of asthma and COPD due to pollution, change in lifestyle, entry of generics and novel therapies in the market. Asia Pacific is anticipated to be the fastest growing market for the forecast period. Emerging economies such India, China due to industrialization, demographic changes, urbanization there is been rise in pollution thus increase in prevalence of asthma and COPD population.

Market Competition Assessment:

Key players in the global asthma and COPD market are Novartis AG, Merck & Co, GlaxoSmithKline Plc, Boehringer Ingelheim Gmbh, Nycomed, Abbott Laboratories, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Pfizer Inc. and others.

Key Market Movements:

- There is a rise in the prevalence of asthma and COPD in both developed and developing countries. In developed countries, the rise in prevalence is mainly due to lifestyle change such as smoking, while in developing countries rise is observed due to presence of most polluted cities in the world and inclusion of smoking in lifestyle

- Introduction of novel technology, strong pipeline, and personalization of medicine is also expected to drive the growth of market.

- With economic development in emerging economies, healthcare awareness, and high disposable income are some of the factors driving the developing countries

For Business Reports : http://www.allbizreports.com/

About Us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Who we are

Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.

Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.

Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.

What we do

We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.

No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.

Media Contact

Name: Chris Smith (Global Sales Manager)

Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US

Ph: 1-800-361-8290

E-mail: [email protected]

Web: http://www.credenceresearch.com